Ensysce Biosciences Inc (ENSC)
0.5747
+0.01
(+1.54%)
USD |
NASDAQ |
May 07, 16:00
0.5747
0.00 (0.00%)
After-Hours: 20:00
Ensysce Biosciences Cash from Financing (TTM): 8.756M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 8.756M |
September 30, 2023 | 9.235M |
June 30, 2023 | 16.82M |
March 31, 2023 | 11.03M |
December 31, 2022 | 8.766M |
Date | Value |
---|---|
September 30, 2022 | 16.01M |
June 30, 2022 | 11.19M |
March 31, 2022 | 19.31M |
December 31, 2021 | 20.31M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
8.756M
Minimum
Dec 2023
20.31M
Maximum
Dec 2021
13.49M
Average
11.19M
Median
Jun 2022
Cash from Financing (TTM) Benchmarks
NovaBay Pharmaceuticals Inc | 1.91M |
Palatin Technologies Inc | 5.553M |
iBio Inc | 10.68M |
Theriva Biologics Inc | 0.625M |
Oragenics Inc | 0.2839M |